Literature DB >> 27799791

Differences in esophageal cancer characteristics and survival between Chinese and Caucasian patients in the SEER database.

Min-Qiang Lin1, Yue-Ping Li2, San-Gang Wu3, Jia-Yuan Sun4, Huan-Xin Lin4, Shi-Yang Zhang5, Zhen-Yu He4.   

Abstract

BACKGROUND: To compare the clinicopathologic characteristics and survival of Chinese and Caucasian esophageal cancer (EC) patients residing in the US, using a population-based national registry (Surveillance Epidemiology and End Results [SEER]) database.
METHODS: Patients with EC were identified from the SEER program from 1988 to 2012. Kaplan-Meier survival methods and Cox proportional hazards regression were performed.
RESULTS: A total of 479 Chinese and 35,748 Caucasian EC patients were identified. Compared with Caucasian patients, the Chinese patients had a later year of diagnosis, remained married after EC was diagnosed, had esophageal squamous cell carcinomas (ESCCs) more frequently, had tumors located in the upper-third and middle-third of the esophagus more frequently, and fewer patients presented with poorly/undifferentiated EC and underwent cancer-directed surgery. In Chinese patients, the incidence of esophageal adenocarcinomas (EACs) increased from 1988 to 2012 (P=0.054), and the majority of EAC patients had tumors located in the lower thoracic esophagus. The overall survival (OS) was not significantly different between Chinese and Caucasian patients (P=0.767). However, Chinese patients with ESCC had a significantly better OS when compared to their Caucasian counterparts, whereas there was no significant difference in the OS between Chinese and Caucasian patients with EAC.
CONCLUSION: The presenting demographic features, tumor characteristics, and outcomes of EC patients differed between Chinese and Caucasian patients residing in the US. Chinese patients diagnosed with EAC tended to share similar clinical features with their Caucasian counterparts, and the Chinese patients with ESCC had better OS than their Caucasian counterparts.

Entities:  

Keywords:  Caucasian; Chinese; SEER; esophageal cancer; survival

Year:  2016        PMID: 27799791      PMCID: PMC5077267          DOI: 10.2147/OTT.S112038

Source DB:  PubMed          Journal:  Onco Targets Ther        ISSN: 1178-6930            Impact factor:   4.147


Introduction

Previous studies have demonstrated that morbidities and survival rates differ among races.1–3 Esophageal squamous cell carcinoma (ESCC) is the most common histologic type of esophageal cancer (EC) in Asian population. Indeed, about half of all EC-related deaths were found in People’s Republic of China and nearly all are due to ESCC.4 In recent years, the incidence of esophageal adenocarcinoma (EAC) has increased rapidly in Western countries, such as the US, and EAC is now the most common histologic subtype in these countries.5–8 The epidemiology and survival of patients with ESCC and EAC have diverse characteristics, which are closely correlated with genetic profile, society, lifestyle, economy, culture, environment, and dietary habits.9,10 Along with the progress of international exchange, an increasing number of Chinese migrate to the US, accounting for a majority of Asian immigrants.11 Due to geographic migration, Chinese immigrants tend to have similar lifestyles and dietary habits as Western residents.12 A nationwide analysis of the demographic, clinicopathologic, and outcomes related to EC in the population-based Surveillance, Epidemiology, and End Results (SEER) database for the Chinese–Caucasian cohort has not been undertaken. Therefore, the purpose of this study was to compare demographic, clinicopathologic, and survival for Chinese and Caucasian EC patients residing in the US using data from the SEER program.

Patients and methods

Patients with a diagnosis of ESCC or EAC were identified using the SEER database from 1988 to 2012 using the International Classification of Disease for Oncology, Third Edition (ICD-O-3). All patients identified as Caucasian and Chinese residing in the US with a primary diagnosis of thoracic ESCC or EAC were included in the analysis. Patients with other racial subgroups and other histologic types were excluded. The permission was obtained to access research data files with the reference number 11252-Nov 2014.13 This study was approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University and Sun Yat-sen University Cancer Center. Informed consent is not required for use of SEER database data, as was confirmed by these ethics committees. The following demographic, clinicopathologic, and outcomes data were collected from the SEER program: year of study, race, sex, age, histologic type, tumor location, histologic grade, SEER stage, marital status, and treatment strategies, including cancer-directed surgery (CDS) and radiotherapy. Vital status, including cause of death and the duration of follow-up, was recorded. The χ2 and Fisher’s exact probability tests were used to analyze the differences between qualitative data. Univariate and multivariate Cox regression analyses were generated to analyze risk factors for overall survival (OS). Multivariate analysis was performed for factors which were significantly associated with OS based on univariate analysis. Calculation of survival rates was plotted by the Kaplan–Meier method and compared using the log-rank test. All data were analyzed with a SPSS statistical software package (version 21.0; IBM Corporation, Armonk, NY, USA). A value of P<0.05 was considered statistically significant.

Results

A total of 36,227 EC patients were identified. Among these patients, the majority (98.7% [35,748/36,227]) were Caucasian, and 1.3% (479/36,227) were Chinese. The demographics, clinical characteristics, and outcomes of all patients are shown in Table 1. There were significant differences in the demographics, clinical characteristics, and treatments between the Chinese and Caucasian patients. The Chinese patients had a later year of diagnosis and remained married after EC was diagnosed. The majority of Chinese patients (81.8% [392/479]) had ESCC, and 67.7% (24,206/35,748) of Caucasian patients had EAC. In addition, more Chinese patients had tumors located in the upper-third and middle-third of the esophagus, and 73.6% of Caucasian patients had lower-third EC. A smaller proportion of Chinese presented with poorly/undifferentiated disease (45.3% vs 51.8%, P=0.006) and underwent CDS (23.2% vs 31.4%, P<0.001), and a larger proportion of Chinese presented with SEER regional stage (41.6% vs 35%, P=0.010).
Table 1

Clinicopathologic characteristics of Chinese and Caucasian patients with esophageal cancer residing in the US from the SEER database

CharacteristicN (%)Chinese (%)Caucasian (%)P-value
Years of study<0.001
 1988–19922,676 (7.4)48 (10.0)2,628 (7.4)
 1993–19973,886 (10.7)77 (16.1)3,809 (10.7)
 1998–20027,572 (20.9)102 (21.3)7,470 (20.9)
 2003–200710,447 (28.8)123 (25.7)10,324 (28.9)
 2008–201211,646 (32.1)129 (26.9)11,517 (32.2)
Age, years0.106
 ≤609,881 (27.3)115 (24.0)9,766 (27.3)
 >6026,346 (72.7)364 (76.0)25,982 (72.7)
Sex0.209
 Male28,263 (78.0)385 (80.4)27,878 (78.0)
 Female7,964 (22.0)94 (19.6)7,870 (22.0)
Tumor location<0.001
 Upper thoracic2,392 (6.6)72 (15.0)2,320 (6.5)
 Middle thoracic7,319 (20.2)198 (41.3)7,121 (19.9)
 Lower thoracic26,516 (73.2)209 (43.6)26,307 (73.6)
Tumor histology<0.001
 Squamous11,934 (32.9)392 (81.8)11,542 (32.3)
 Adenocarcinoma24,293 (67.1)87 (18.2)24,206 (67.7)
Grade (n=30,421)0.006
 Well-differentiated1,896 (6.2)19 (4.8)1,877 (6.3)
 Moderately differentiated12,787 (42.0)196 (49.9)12,591 (41.9)
 Poorly/undifferentiated15,738 (51.7)178 (45.3)15,560 (51.8)
SEER stage (n=31,867)0.010
 Localized stage9,155 (28.7)96 (23.5)9,059 (28.8)
 Regional stage11,177 (35.1)170 (41.6)11,007 (35.0)
 Distant stage11,535 (36.2)143 (35.0)11,392 (36.2)
Surgery (n=35,717)<0.001
 No24,557 (68.8)365 (76.8)24,192 (68.6)
 Yes11,160 (31.2)110 (23.2)11,050 (31.4)
Radiotherapy (n=35,132)0.109
 No15,612 (44.4)190 (40.8)15,422 (44.5)
 Yes19,520 (55.6)276 (59.2)19,244 (55.5)
Marital status (n=34,851)<0.001
 Married26,815 (76.9)393 (83.8)26,422 (76.8)
 Not married8,036 (23.1)76 (16.2)7,960 (23.2)
Mortality0.737
 Alive6,295 (17.4)86 (18.0)6,209 (17.4)
 Dead29,932 (82.6)393 (82.0)29,539 (82.6)
Esophageal cancer-related death0.130
 No13,378 (36.9)161 (33.6)13,217 (37.0)
 Yes22,849 (63.1)318 (66.4)22,531 (63.0)

Abbreviation: SEER, Surveillance Epidemiology and End Results.

The demographics and tumor characteristics of ESCC and EAC are shown in Table 2. In Chinese patients, the incidence of EAC increased from 1988 to 2012 (P=0.054). Most of the EAC patients (81.6% [71/87]) had tumors located in the lower thoracic esophagus, 50% (36/72) of EAC patients had SEER distant stage, and only 31.8% of patients had distant stage of ESCC. In Caucasian patients, there were significant differences in the demographics, clinical characteristics, and treatments between the ESCC and EAC patients.
Table 2

Clinicopathologic characteristics of ESCC and EAC patients between Chinese and Caucasians residing in the US from the SEER database

CharacteristicChinese
Caucasian
N (%)ESCC (%)EAC (%)P-valueN (%)ESCC (%)EAC (%)P-value
Years of study0.054<0.001
 1988–199248 (10.0)42 (10.7)6 (6.9)2,628 (7.4)1,416 (12.3)1,212 (5.0)
 1993–199777 (16.1)62 (15.8)15 (17.2)3,809 (10.7)1,684 (14.6)2,125 (8.8)
 1998–2002102 (21.3)92 (23.5)10 (11.5)7,470 (20.9)2,545 (22.0)4,925 (20.3)
 2003–2007123 (25.7)98 (25.0)25 (28.7)10,324 (28.9)2,980 (25.8)7,344 (30.3)
 2008–2012129 (26.9)98 (25.0)31 (35.6)11,517 (32.2)2,917 (25.3)8,600 (35.5)
Age, years0.806<0.001
 ≤60115 (24.0)95 (24.2)20 (23.0)9,766 (27.3)2,505 (21.7)7,261 (30.0)
 >60364 (76.0)297 (75.8)67 (77.0)25,982 (72.7)9,037 (78.3)16,945 (70.0)
Sex0.983<0.001
 Male385 (80.4)315 (80.4)70 (80.5)7,870 (22.0)4,525 (39.2)3,345 (13.8)
 Female94 (19.6)77 (19.6)17 (19.5)27,878 (78.0)7,017 (60.8)20,861 (86.2)
Tumor location<0.001<0.001
 Upper thoracic72 (15.0)69 (17.6)3 (3.4)2,320 (6.5)2,000 (17.3)320 (1.3)
 Middle thoracic198 (41.3)185 (47.2)13 (14.9)7,121 (19.9)5,115 (44.3)2,006 (8.3)
 Lower thoracic209 (43.6)138 (35.2)71 (81.6)26,307 (73.6)4,427 (38.4)21,880 (90.4)
Grade0.021<0.001
 Well-differentiated19 (4.8)16 (5.0)3 (4.2)1,877 (6.3)585 (6.1)1,292 (6.3)
 Moderately differentiated196 (49.9)170 (53.0)26 (36.1)12,591 (41.9)4,336 (44.9)8,255 (40.5)
 Poorly/undifferentiated178 (45.3)135 (42.0)43 (59.7)15,560 (51.8)4,727 (49.0)10,833 (53.2)
SEER stage0.008<0.001
 Localized stage96 (23.5)86 (25.5)10 (13.9)9,059 (28.8)3,132 (32.4)5,927 (27.2)
 Regional stage170 (41.6)144 (42.7)26 (36.1)11,007 (35.0)3,645 (37.7)7,362 (33.8)
 Distant stage143 (35.0)107 (31.8)36 (50.0)11,392 (36.2)2,892 (29.9)8,500 (39.0)
Surgery0.546<0.001
 No365 (76.8)296 (76.3)69 (79.3)24,192 (68.6)8,841 (77.7)15,351 (64.3)
 Yes110 (23.2)92 (23.7)18 (20.7)11,050 (31.4)2,540 (22.3)8,510 (35.7)
Radiotherapy0.009<0.001
 No190 (40.8)146 (38.0)44 (53.7)15,422 (44.5)4,201 (37.8)11,221 (47.7)
 Yes276 (59.2)238 (62.0)38 (46.3)19,244 (55.5)6,923 (62.2)12,321 (52.3)
Marital status0.089<0.001
 Married393 (83.8)327 (85.2)66 (77.6)26,422 (76.8)8,252 (74.3)18,170 (78.1)
 Not married76 (16.2)57 (14.8)19 (22.4)7,960 (23.2)2,854 (25.7)5,106 (21.9)

Abbreviations: ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma; SEER, Surveillance Epidemiology and End Results.

Kaplan–Meier analysis demonstrated no difference in OS rates between Chinese and Caucasian patients (P=0.760); however, the results differed when stratified by histologic type. Chinese patients with ESCC had a significantly better OS than Caucasian patients (P=0.001; Figure 1A). In contrast, Caucasian patients with EAC had a significantly better OS compared to Chinese patients (P=0.004; Figure 1B).
Figure 1

Overall survival of esophageal cancer in Chinese and Caucasian patients.

Notes: (A) Chinese patients with esophageal squamous cell carcinomas showing significantly better overall survival than Caucasian patients (P=0.001). (B) Caucasian patients with esophageal adenocarcinoma showing significantly better overall survival compared to Chinese patients (P=0.004).

The results of the univariate analysis on OS are shown in Table 3. The OS was not significantly different between Chinese and Caucasian patients (P=0.767). Chinese race was associated with a better OS in patients with ESCC (P=0.001). Caucasian race was associated with a better OS in patients with EAC (P=0.006) (Table S1).
Table 3

Univariate Cox analysis of overall survival of patients with esophageal cancer

CharacteristicEntire cohort
Chinese
Caucasian
HR95% CIP-valueHR95% CIP-valueHR95% CIP-value
Years of study (continuous variable)0.9860.982–0.985<0.0010.9750.960–0.990<0.0010.9840.982–0.985<0.001
Age, years (continuous variable)1.0191.018–1.020<0.0011.0151.006–1.024<0.0011.0201.018–1.021<0.001
Sex
 Male111
 Female1.0741.045–1.103<0.0011.0430.811–1.3410.7441.0741.045–1.104<0.001
Tumor location
 Upper thoracic111
 Middle thoracic0.9850.937–1.0350.5510.8260.610–1.1190.2180.9910.942–1.0420.711
 Lower thoracic0.8430.806–0.881<0.0010.9170.678–1.2400.5740.8420.804–0.881<0.001
Tumor histology
 Squamous111
 Adenocarcinoma0.8550.835–0.876<0.0011.3721.064–1.7690.0150.8460.829–0.870<0.001
Grade
 Well-differentiated111
 Moderately differentiated1.3241.251–1.400<0.0011.0250.603–1.7430.9271.3281.255–1.406<0.001
 Poorly/undifferentiated1.6681.578–1.764<0.0011.4210.836–2.4160.1951.6721.581–1.768<0.001
SEER stage
 Localized stage111
 Regional stage1.3791.335–1.424<0.0011.1010.830–1.4620.5041.3831.339–1.428<0.001
 Distant stage2.9022.810–2.996<0.0011.9091.432–2.543<0.0012.9212.828–3.017<0.001
Surgery
 No111
 Yes0.3730.363–0.383<0.0010.4870.381–0.624<0.0010.3710.361–0.381<0.001
Radiotherapy
 No111
 Yes0.8240.805–0.844<0.0010.8300.676–1.0200.0760.8240.805–0.844<0.001
Marital status
 Married111
 Not married1.0951.066–1.126<0.0011.1290.864–1.4740.3741.0951.065–1.126<0.001
Ethnicity
 Chinese1
 Caucasian1.0150.919–1.1220.767

Abbreviations: SEER, Surveillance Epidemiology and End Results; HR, hazard ratio; CI, confidence interval.

The multivariate Cox proportional hazards regression model was adjusted for year of study, age, sex, tumor location, histologic grade, SEER stage, marital status, surgical treatment, and radiotherapy (Table 4). Chinese race was independently associated with a better OS in patients with ESCC compared to Caucasian patients (hazard ratio [HR] =1.330; 95% confidence interval [CI] =1.159–1.527, P<0.001). There was no significant difference in OS between Chinese and Caucasian patients with EAC (HR =0.853; 95% CI =0.642–1.132, P=0.271) (Table S2).
Table 4

Multivariate Cox analysis of overall survival of patients with esophageal cancer

CharacteristicEntire cohort
Chinese
Caucasian
HR95% CIP-valueHR95% CIP-valueHR95% CIP-value
Years at study (continuous variable)0.9740.971–0.976<0.0010.9640.947–0.980<0.0010.9740.971–0.976<0.001
Age, years (continuous variable)1.0181.017–1.019<0.0011.0141.003–1.0240.0131.0181.017–1.019<0.001
Sex
 Male11
 Female0.9270.895–0.960<0.0010.9180.887–0.951<0.001
Tumor location
 Upper thoracic1
 Middle thoracic1.0960.997–1.1300.0631.0741.008–1.1450.027
 Lower thoracic0.9990.943–1.0600.9840.9990.942–1.0600.984
Tumor histology
 Squamous111
 Adenocarcinoma1.0110.975–1.0490.5461.5211.144–2.0210.0040.9990.963–1.0370.966
Grade
 Well-differentiated11
 Moderately differentiated1.1901.116–1.269<0.0011.1931.119–1.272<0.001
 Poorly/undifferentiated1.4091.323–1.501<0.0011.4041.317–1.496<0.001
SEER stage
 Localized stage111
 Regional stage1.5351.480–1.593<0.0011.2610.941–1.6900.1201.5441.487–1.602<0.001
 Distant stage2.3932.300–2.490<0.0011.6811.234–2.2910.0012.4112.317–2.509<0.001
Surgery
 No111
 Yes0.4330.418–0.448<0.0010.5070.382–0.674<0.0010.4320.417–0.447<0.001
Radiotherapy
 No11
 Yes0.6790.659–0.699<0.0010.6790.659–0.699<0.001
Marital status
 Married11
 Not married1.1761.137–1.216<0.0011.1721.133–1.212<0.001

Abbreviations: SEER, Surveillance Epidemiology and End Results; HR, hazard ratio; CI, confidence interval.

Stratifying analysis according to race was performed (Tables 3 and 4). Chinese patients with ESCC had a better OS than EAC patients based on univariate (P=0.015) and multivariate (P<0.001) analyses (Figure 2A). In Caucasian population, EAC patients had a better OS than ESCC patients based on univariate analysis (P<0.001; Figure 2B), but not in multivariate analysis (P=0.996).
Figure 2

Overall survival of esophageal cancer in Chinese (A) and Caucasian (B) patients by the tumor histology.

Discussion

In the Chinese population, ESCC was the dominant type of EC,4 whereas a majority of the American population were EAC, especially for Caucasians from the US.5,6 Currently, comparative studies analyzing the morbidity and prognosis between the Chinese and Caucasians populations have been rarely reported. In this study, the SEER database was used for a comparative analysis. It was found that the Chinese and Caucasians patients with EC have different clinical features and outcomes. Nevertheless, ethnicity exerts no effect upon the survival of all EC patients. Interestingly, subgroup analysis demonstrated that survival difference exists among different populations with diverse histologic types of EC. In addition, the survival rate of Chinese ESCC patients was higher compared with Caucasians; however, the same phenomenon was not demonstrated with respect to EAC. Based on the analysis, tumor location and histologic type were the major differences between the Chinese and Caucasian races. Caucasian patients were mainly diagnosed with lower thoracic EC and EAC, whereas middle and upper thoracic EC and ESCC were mainly observed in the Chinese population, which is consistent with most previous findings.14–16 In the Western countries, Barrett’s esophagus is the primary risk factor for EAC.17 Nevertheless, among 5,041 EC patients from a high-risk EC region in People’s Republic of China, 217 patients (4.3%) were diagnosed with EAC, and only 4.6% (10/217) of these patients had Barrett’s esophagus.18 In another epidemiologic study conducted in People’s Republic of China, only 1.5% of 4,422 EC patients were diagnosed with EAC.19 The current study showed that the prevalence of EAC was 18.2% in Chinese immigrants, which was significantly higher compared with the Chinese counterparts who reside in People’s Republic of China. In addition, the incidence of EAC in Chinese patients with EC tended to gradually ascend between 1988 and 2012 (P=0.054). Moreover, the location of EAC was similar to the US counterparts, predominantly involving the lower thoracic EC. This phenomenon probably results from the fact that the Chinese immigrants become more accustomed to the life and dietary habits of local residents in the US. It was also demonstrated that the age of onset of ESCC and EAC significantly differed in the Caucasian population; however, the histologic type of EC was not correlated with the age of onset (P=0.806). Due to the lack of data with regard to migration time in the SEER database, it was difficult to evaluate the difference in EC morbidity in the Chinese race based upon the duration of dietary alteration. Esophagectomy remains the primary therapeutic strategy for EC. In this study, the survival rate of patients undergoing CDS was higher than their counterparts who did not. SEER data revealed that the localized and regional staging was observed in 65.1% of the Chinese population and 63.8% of their Caucasian counterparts. The probability of the Chinese race undergoing CDS was 23.2%, which was slightly lower compared with 31.4% in the Caucasian population; this difference was likely related to the higher surgical difficulty in patients with upper-thoracic EC compared with lower-thoracic EC. Previous studies have reported that ESCC patients are less likely to present with lymph node metastasis and distant recurrence.20,21 In this study, only 89 Chinese, but 8,728 Caucasian patients underwent lymph node dissection. Consequently, it is unreasonable to explicitly compare lymph node metastases between the two populations. The incidence of newly diagnosed distant metastasis was 35% in the Chinese and 36.2% in the Caucasian population, with no statistical significance. In addition, the results of this study showed that the Chinese subgroup with ESCC had a significantly better OS when compared to their Caucasian counterparts, whereas no significant difference in the survival rate was observed between the Chinese and Caucasian patients with EAC. It has been demonstrated that the survival rate of Asian population with endometrial carcinoma, rectal cancer, liver cancer, and non-small-cell lung cancer was higher compared with the non-Hispanic white population.22–25 In this study, the survival rate of ESCC patients was higher compared to that of EAC patients in the Chinese population, whereas the survival rate of ESCC and EAC patients did not significantly differ in their Caucasian counterparts. The discrepancy in survival rate among different populations with diverse histologic types probably reflects the following observations. First, there are different risk factors which can induce ESCC and EAC.9,10 Second, a genetic difference in EC exists between the Chinese and Caucasian populations.26–33 Consequently, a genetic difference might be used to evaluate the clinical prognosis and therapeutic strategy for EC in subsequent investigations. This study acknowledges several limitations. First, this was a retrospective study. Second, a lack of data in SEER, including chemotherapeutic regimen and dose, local and distant recurrence data, and comorbidities, limited the ability to determine the true etiology in these two races. A strength of this study was that this is the largest study evaluating EC outcomes in Chinese compared to Caucasians residing in the US. Although retrospective reviews should not carry the power of prospective studies, no prospective assessment of the outcome of Chinese and Caucasians in EC exists.

Conclusion

This study demonstrated that the presenting demographic features, tumor characteristics, and outcomes of EC patients differ between Chinese and Caucasians residing in the US. Chinese patients diagnosed with EAC tend to share clinical features which are similar to their Caucasian counterparts. Chinese patients with ESCC had a better OS than Caucasians. Further studies should be conducted to confirm these conclusions. Univariate Cox analysis of overall survival of patients with esophageal squamous cell carcinoma and esophageal adenocarcinoma Abbreviations: SEER, Surveillance Epidemiology and End Results; HR, hazard ratio; CI, confidence interval; ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma. Multivariate Cox analysis of overall survival of patients with esophageal squamous cell carcinoma and esophageal adenocarcinoma Note: –, No significance of the tumor location in the univariate Cox analysis. Abbreviations: SEER, Surveillance Epidemiology and End Results; HR, hazard ratio; CI, confidence interval; ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma.
Table S1

Univariate Cox analysis of overall survival of patients with esophageal squamous cell carcinoma and esophageal adenocarcinoma

CharacteristicESCC
EAC
HR95% CIP-valueHR95% CIP-value
Years of study (continuous variable)0.9900.988–0.993<0.0010.9810.979–0.984<0.001
Age, years (continuous variable)1.0181.016–1.020<0.0011.0191.018–1.021<0.001
Sex
 Male11
 Female0.9200.885–0.957<0.0011.1361.091–1.182<0.001
Tumor location
 Upper thoracic11
 Middle thoracic0.9740.922–1.0280.3401.0350.909–1.1780.605
 Lower thoracic0.9520.901–1.0070.0850.8490.751–0.9580.008
Grade
 Well-differentiated11
 Moderately differentiated1.3311.210–1.464<0.0011.3071.219–1.402<0.001
 Poorly/undifferentiated1.4701.336–1.616<0.0011.7761.659–1.903<0.001
SEER stage
 Localized stage11
 Regional stage1.1811.121–1.243<0.0011.5221.461–1.586<0.001
 Distant stage2.1602.046–2.281<0.0013.4713.334–3.614<0.001
Surgery
 No11
 Yes0.4820.458–0.506<0.0010.3330.322–0.344<0.001
Radiotherapy
 No11
 Yes0.6740.647–0.701<0.0010.8760.851–0.901<0.001
Marital status
 Married11
 Not married1.0831.035–1.1320.0011.0911.054–1.129<0.001
Ethnicity
 Chinese11
 Caucasian1.2021.075–1.3440.0010.7250.577–0.9110.006

Abbreviations: SEER, Surveillance Epidemiology and End Results; HR, hazard ratio; CI, confidence interval; ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma.

Table S2

Multivariate Cox analysis of overall survival of patients with esophageal squamous cell carcinoma and esophageal adenocarcinoma

CharacteristicESCC
EAC
HR95% CIP-valueHR95% CIP-value
Years of study (continuous variable)0.9790.975–0.982<0.0010.9710.968–0.974<0.001
Age, years (continuous variable)1.0171.014–1.019<0.0011.0181.017–1.020<0.001
Sex
 Male11
 Female0.8700.828–0.915<0.0010.9720.925–1.0220.273
Tumor location
 Upper thoracic1
 Middle thoracic1.0330.880–1.2130.692
 Lower thoracic0.9020.776–1.0500.183
Grade
 Well-differentiated11
 Moderately differentiated1.2131.085–1.3560.0011.1671.079–1.262<0.001
 Poorly/undifferentiated1.2121.084–1.3550.0011.4911.380–1.611<0.001
SEER stage
 Localized stage11
 Regional stage1.3551.276–1.438<0.0011.6331.556–1.715<0.001
 Distant stage1.9951.869–2.130<0.0012.6512.521–2.788<0.001
Surgery
 No11
 Yes0.4450.417–0.475<0.0010.4270.409–0.446<0.001
Radiotherapy
 No11
 Yes0.5630.534–0.594<0.0010.7340.709–0.761<0.001
Marital status
 Married11
 Not married1.1901.125–1.260<0.0011.1511.107–1.203<0.001
Ethnicity
 Chinese11
 Caucasian1.3301.159–1.527<0.0010.8530.642–1.1320.271

Note: –, No significance of the tumor location in the univariate Cox analysis.

Abbreviations: SEER, Surveillance Epidemiology and End Results; HR, hazard ratio; CI, confidence interval; ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma.

  31 in total

Review 1.  Epidemiologic trends in esophageal and gastric cancer in the United States.

Authors:  Linda Morris Brown; Susan S Devesa
Journal:  Surg Oncol Clin N Am       Date:  2002-04       Impact factor: 3.495

2.  Racial disparities in esophageal cancer treatment and outcomes.

Authors:  Alexander J Greenstein; Virginia R Litle; Scott J Swanson; Celia M Divino; Stuart Packer; Thomas G McGinn; Juan P Wisnivesky
Journal:  Ann Surg Oncol       Date:  2007-11-07       Impact factor: 5.344

3.  Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma.

Authors:  Christophe Mariette; Laetitia Finzi; Guillaume Piessen; Isabelle Van Seuningen; Jean Pierre Triboulet
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

4.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

5.  Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations.

Authors:  Chen Wu; Zhibin Hu; Zhonghu He; Weihua Jia; Feng Wang; Yifeng Zhou; Zhihua Liu; Qimin Zhan; Yu Liu; Dianke Yu; Kan Zhai; Jiang Chang; Yan Qiao; Guangfu Jin; Zhe Liu; Yuanyuan Shen; Chuanhai Guo; Jianhua Fu; Xiaoping Miao; Wen Tan; Hongbing Shen; Yang Ke; Yixin Zeng; Tangchun Wu; Dongxin Lin
Journal:  Nat Genet       Date:  2011-06-05       Impact factor: 38.330

6.  Endometrial cancer in Asian and American Indian/Alaskan Native women: tumor characteristics, treatment and outcome compared to non-Hispanic white women.

Authors:  Haider Mahdi; Cary Jo Schlick; Li-Lian Kowk; Mehdi Moslemi-Kebria; Chad Michener
Journal:  Gynecol Oncol       Date:  2013-12-03       Impact factor: 5.482

7.  Global incidence of oesophageal cancer by histological subtype in 2012.

Authors:  Melina Arnold; Isabelle Soerjomataram; Jacques Ferlay; David Forman
Journal:  Gut       Date:  2014-10-15       Impact factor: 23.059

8.  Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States.

Authors:  Avo Artinyan; Brian Mailey; Nicelio Sanchez-Luege; Joshua Khalili; Can-Lan Sun; Smita Bhatia; Lawrence D Wagman; Nicholas Nissen; Steven D Colquhoun; Joseph Kim
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

Review 9.  Epidemiologic differences in esophageal cancer between Asian and Western populations.

Authors:  Han-Ze Zhang; Guang-Fu Jin; Hong-Bing Shen
Journal:  Chin J Cancer       Date:  2012-04-13

10.  Patterns of lymph node recurrence after radical surgery impacting on survival of patients with pT1-3N0M0 thoracic esophageal squamous cell carcinoma.

Authors:  Xiao-Li Chen; Tian-Wu Chen; Zhi-Jia Fang; Xiao-Ming Zhang; Zhen-Lin Li; Hang Li; Hong-Jie Tang; Li Zhou; Dan Wang; Zishu Zhang
Journal:  J Korean Med Sci       Date:  2014-01-28       Impact factor: 2.153

View more
  8 in total

1.  Overview of esophageal cancer.

Authors:  Ghulam Abbas; Mark Krasna
Journal:  Ann Cardiothorac Surg       Date:  2017-03

Review 2.  Esophageal carcinoma: Towards targeted therapies.

Authors:  Ali Fatehi Hassanabad; Rania Chehade; Daniel Breadner; Jacques Raphael
Journal:  Cell Oncol (Dordr)       Date:  2019-12-17       Impact factor: 6.730

3.  Better Prognosis and Survival in Esophageal Cancer Survivors After Comorbid Second Primary Malignancies: A SEER Database-Based Study.

Authors:  Jiayue Ye; Sheng Hu; Wenxiong Zhang; Deyuan Zhang; Yang Zhang; Dongliang Yu; Jinhua Peng; Jianjun Xu; Yiping Wei
Journal:  Front Surg       Date:  2022-05-06

4.  Comparison of prognostic factors of esophageal cancer between a Chinese cohort and the Surveillance, Epidemiology, and End Results (SEER) database: a retrospective cohort study.

Authors:  Bin Hu; Yiyao Zhu; Xiaobo Wu
Journal:  J Gastrointest Oncol       Date:  2022-04

5.  Racial disparities in the survival time of patients with hepatocellular carcinoma and intrahepatic cholangiocarcinoma between Chinese patients and patients of other racial groups: A population-based study from 2004 to 2013.

Authors:  Fenggang Ren; Jing Zhang; Zhongyang Gao; Haoyang Zhu; Xue Chen; Wenyan Liu; Zhao Xue; Weiman Gao; Rongqian Wu; Yi Lv; Liangshuo Hu
Journal:  Oncol Lett       Date:  2018-10-05       Impact factor: 2.967

6.  Clinical outcomes for 61 cases of hypopharyngeal cancer with synchronous esophageal cancer.

Authors:  Shixuan Yang; Shuang Yang; Wenjun Liao; Rui Huang; Baisen Li; Shun Lu; Chao Li; Zhaohui Wang; Chunhua Li; Jiao Pei; Hao Wen; Shichuan Zhang
Journal:  J Radiat Res       Date:  2019-10-23       Impact factor: 2.724

7.  PTTG1 cooperated with GLI1 leads to epithelial-mesenchymal transition in esophageal squamous cell cancer.

Authors:  Wang Feng; Xuan Xiaoyan; Li Shenglei; Liu Hongtao; Jiang Guozhong
Journal:  Oncotarget       Date:  2017-09-27

8.  Second primary malignancy in patients with esophageal adenocarcinoma and squamous cell carcinoma.

Authors:  Guoqing Zhang; Bin Wu; Xiaofei Wang; Jindong Li
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.